RGEN

Repligen Corp. 10-Q Summary: Period Ended September 30, 1998

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for Repligen Corporation for the three and six months ended September 30, 1998. Repligen is a biotechnology company developing drugs for cancer, organ transplant, and autoimmune diseases. Its primary activities include proprietary drug discovery (specifically angiogenesis inhibitors), the development of the biopharmaceutical CTLA4-Ig, and the manufacturing of affinity chromatography products for protein pharmaceutical production.

Key Financial Metrics

Revenue Breakdown (Six Months): Research and development ($738,438), Product ($426,149), Investment income ($119,182), and Other ($70,836).

Expense Breakdown (Six Months): Research and development ($931,025), Selling, general and administrative ($711,243), and Cost of products sold ($254,273).

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 51% ($259,000) for the quarter and 15% ($176,000) year-to-date compared to the prior year. This was driven primarily by a 183% increase in research and development revenue, including a licensing fee from Neocrin, Inc.
• Product Sales Decline: Product revenues decreased 23% ($60,000) for the quarter, attributed to the absence of a significant reagent order present in the prior year.
• Expense Increases: Total expenses rose 29% for the quarter and 21% year-to-date. R&D expenses increased 30% year-to-date due to expanded staffing for proprietary drug discovery. SG&A expenses increased due to higher patent, legal, and shareholder service costs.
• Cost of Goods Sold: Cost of products sold as a percentage of product revenue increased from 31% to 72% for the quarter and from 42% to 59% year-to-date. This was caused by a change in product mix and increased inventory reserves for new protein A products.
• Cash Flow: Net cash used in operating activities was $546,719 for the six months ended September 30, 1998, compared to $392,245 in the prior year. Cash and cash equivalents decreased by $625,670 during the period.

Outlook, Risks, and Contingencies

• Liquidity: Management believes current cash equivalents and marketable securities are sufficient to meet working capital and capital expenditure requirements for the next 24 months, despite anticipated increases in operating costs.
• Legal Proceedings: On July 17, 1998, Repligen filed a complaint against Bristol-Myers Squibb Corporation regarding a 1995 patent for CTLA4-Ig. Repligen seeks to correct inventorship to secure shared rights. Failure could restrict the commercialization of CTLA4-Ig for certain applications.
• Collaboration Risks: Future revenue from collaborative partners and licensees is contingent on the continuation of these agreements and the progression of clinical evaluations, which cannot be assured.
• Year 2000 Compliance: The company is addressing Year 2000 issues in its IT systems and expects full compliance by the end of 1999. No contingency plan exists yet if compliance is not achieved timely, though costs are not expected to be material.

Investor Verification Checklist

• Verify the status and potential outcome of the patent litigation against Bristol-Myers Squibb regarding CTLA4-Ig.
• Confirm the sustainability of the 51% revenue growth, specifically the reliance on R&D contracts and licensing fees versus product sales.
• Assess the impact of rising cost of goods sold margins (72% for the quarter) on future profitability of product lines.
• Monitor the burn rate of cash ($626,000 decrease in six months) against the 24-month liquidity runway projection.
• Review the progress of the proprietary angiogenesis inhibitor program and the clinical evaluation of CTLA4-Ig for Graft Versus Host Disease.